Subcutaneous Panniculitis-like T-cell Lymphoma (SPTCL) is a rare subtype of cutaneous T-cell lymphoma derived from alpha/beta cytotoxic T-cells. It is known to follow an indolent course with a favorable prognosis. We review current therapies used to treat this rare entity in order to increase awareness about possible options. No standardized therapy for SPTL currently exists. Local radiotherapy for indolent local disease has been found successful. For indolent disease with a more generalized distribution, immunosuppressive agents as well as lowdose chemotherapy may be used. For aggressive presentations, combination chemotherapy, anthracycline-based regimens, fludarabine-based regimens, and rarely high-dose chemotherapy followed by hematopoietic stem cell transplant (SCT) with moderate success. By being aware of possible therapeutic options, a physician can recommend the most appropriate treatment for the individual.